ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Background of ICI & Highlights in Oncology"
Episode Synopsis
Immune-checkpoint inhibitors (ICIs) represent a significant breakthrough in the field of cancer over the last 10-15 yearsMultiple ICIs currently available as IV therapies (8 PD-1/PD-L1 agents approved since 2011Robust survival benefit seen with ICI across multiple tumor typesIV ICI therapy requires line access and creates increased chair timeSubcutaneous (SC) ICI options provide increased patient convenience and operational efficienciesSC products may increase nurse resources due to time spent administering
More episodes of the podcast Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)
Summary of Key Concepts
31/07/2025
In God we trust